The FDA Explained: An Interview with Dr. Harpreet Singh
Lung Cancer ConsideredDuring an episode of IASLC’s Lung Cancer Considered podcast, Dr. Singh provided insight into the US agency’s approval process. Here are some highlights. Read more
A New Standard of Care in EGFR-Positive NSCLC Unresponsive to TKIs?
Myung-Ju Ahn, MD, PhDInterim analysis from ORIENT-31 demonstrates a four-drug regimen may be a reasonable option for patients whose disease has progressed on EGFR TKIs. Read more
The OncoKB Precision Oncology Knowledge Base: A Q&A with Dr. Debyani Chakravarty
Joy CurzioFinding precision treatments after molecular testing requires a tool for reviewing actionable mutations. Read more
Targeting Angiogenesis in Mesothelioma: Insights From MAPS and RAMES
Nirosha D. Perera, MD+more
Without validated biomarkers for anti-angiogenesis therapy, VEGF inhibitors are increasingly being investigated. Read more
Approval opens the door for an immunotherapy-based treatment option prior to surgery for the first time. Read more
Low-Dose CT, ctDNA May Partner for Lung Cancer Detection
Leah LawrenceLiquid biopsy tool may be useful in high-risk individuals unwilling or unable to undergo LDCT. Read more
Award Lecture Highlights Tumor Evolution Through Liquid Biopsy
Leah LawrenceThe UK’s Dr. Charles Swanton received the ISLB’s 2021 award for outstanding scientific contribution. Read more
Patient Perspective: Anxiety Follows Abrupt Departure From Clinical Trial
Julie Swedberg, CPAThe onboarding required to participate in a clinical trial is extensive. The offboarding, however, can feel like abandonment for some patients. Read more
Determining the Most Effective Chemotherapy Regimen in Patients With Advanced KRAS-Mutated NSCLC: the NVALT22 study
Sophie M. Ernst, MD+more
Study tests combination of taxanes with an angiogenesis inhibitor in search for better outcomes for patients with advanced KRAS-mutated NSCLC. Read more
Novel Targets and Therapies: KEAP1- and NFE2L2-Mutant Squamous Cell Lung Cancer
Paul Paik, MD+more
During an interview with ILCN, Drs. Paul Paik and Jonathan Reiss discuss the implications of KEAP1 and NFE2L2 mutations in NSCLC. Read more